However, CaSR activators (such as Ca2+, NPS, R467) did not enhance IL-6 expression in these cells, indicating that CaSR agonists exerting a mitogenic effect on myeloma cells seemed to be independent of IL-6 actions [57]. Here, CASR is linked to plasma cell myeloma.